Drug
Anecortave acetate clinical trials
- studies test it
- 27
- open now
- 0
- in phase 3
- 10
- first study started
- 1999
How studies write it
Studies that test it under each name
Name
Studies by the year they started
26 studies that test it; most in 2002 (5)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2002 | 5 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 16
- Phase 3
- 10
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 10
Alcon Research (17) · Manhattan Eye, Ear & Throat Hospital (8) · Texas Retina Associates (1) · Cornea Research Foundation of America (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses anecortave acetate is read from its arms, and is right about nine times in ten.
Testing it · 27
- Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant PatientsTerminatedNot applicableCornea Research Foundation of AmericaNCT00884039Written as anecortave acetate
- Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMDCompletedPhase 3Alcon ResearchNCT00041483Written as Anecortave Acetate 15 mg sterile suspension
- Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMDTerminatedPhase 3Alcon ResearchNCT00065728Written as Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
- A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular HypertensionTerminatedPhase 2Alcon ResearchNCT00788541Written as Anecortave Acetate Sterile Suspension, 60 mg/ML
- An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMDCompletedPhase 3Alcon ResearchNCT00058994Written as anecortave acetate
- 24 Hour IOP Lowering Efficacy of AL-3789CompletedPhase 2Alcon ResearchNCT00643669Written as AL-3789 Sterile Suspension
- Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) ElevationCompletedPhase 2Alcon ResearchNCT00315640Written as Anecortave Acetate Sterile Suspension, 60 mg/mL
- Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)CompletedPhase 3Alcon ResearchNCT00051129Written as Anecortave Acetate 15 mg sterile suspension
- Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2/3Alcon ResearchNCT00691717Written as Anecortave Acetate Sterile Suspension, 30 mg/mL
- Anecortave Acetate in Patients With Open-angle GlaucomaCompletedPhase 2Alcon ResearchNCT00320203Written as Anecortave Acetate Sterile Suspension, 30 mg/mL
- Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle GlaucomaCompletedPhase 2Alcon ResearchNCT00451152Written as Anecortave Acetate Sterile Suspension, 30 mg/mL
- Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)CompletedPhase 3Alcon ResearchNCT00299507Written as Anecortave Acetate Sterile Suspension, 30 mg/mL
- Anecortave Acetate Risk Reduction Trial (AART)TerminatedPhase 3Alcon ResearchNCT00332657Written as Anecortave Acetate Sterile Suspension, 30 mg/mL
- Anecortave Acetate Risk-Reduction Trial (AART)TerminatedPhase 3Alcon ResearchNCT00333216Written as Anecortave Acetate Sterile Suspension, 30 mg/mL
- Anecortave Acetate Risk-Reduction Trial (AART)TerminatedPhase 3Alcon ResearchNCT00307398Written as Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
- Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave AcetateCompletedPhase 1/2Manhattan Eye, Ear & Throat HospitalNCT00489840Written as Anecortave Acetate Sterile suspension 15 mg
- Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)CompletedPhase 1Manhattan Eye, Ear & Throat HospitalNCT00211419Written as Anecortave Acetate 15 mg
- Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)CompletedPhase 2Manhattan Eye, Ear & Throat HospitalNCT00211315Written as anecortave acetate
- Prophylactic Anecortave Acetate in Patients With a Retisert ImplantCompletedPhase 1Texas Retina AssociatesNCT00570479Written as anecortave acetate
- A Multi-Dose Study With a Treatment for Open-Angle GlaucomaWithdrawnPhase 2/3Alcon ResearchNCT00705770Written as Anecortave Acetate
Codes
What other systems call anecortave acetate · ClinicalTrials.gg INT004291
- MeSH (NLM) C418047anecortave acetateOne source NLM
- UNII (FDA) Y0PC411K4TANECORTAVE ACETATEConfirmed FDA, NLM, Wikidata
- Wikidata Q4761567anecortave acetateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171908Anecortave AcetateOne source FDA
- DrugBank DB05288One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C418047 | anecortave acetate | One source NLM |
| UNII (FDA) | Y0PC411K4T | ANECORTAVE ACETATE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4761567 | anecortave acetate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171908 | Anecortave Acetate | One source FDA |
| DrugBank | DB05288 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.